Last reviewed · How we verify
Optimized bismuth quadruple therapy
Optimized bismuth quadruple therapy is a Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen Small molecule drug developed by Pontificia Universidad Catolica de Chile. It is currently FDA-approved for Helicobacter pylori infection eradication. Also known as: Rama Intervención.
Bismuth quadruple therapy combines bismuth subsalicylate with three antimicrobial agents to eradicate Helicobacter pylori infection through multiple mechanisms of action.
Optimized bismuth quadruple therapy is a treatment for Helicobacter pylori infection, which involves a combination of medications including bismuth. Bismuth, a small molecule, acts as a coagulation factor XII activator, according to its mechanism of action.
At a glance
| Generic name | Optimized bismuth quadruple therapy |
|---|---|
| Also known as | Rama Intervención |
| Sponsor | Pontificia Universidad Catolica de Chile |
| Drug class | Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This regimen typically consists of bismuth subsalicylate, a proton pump inhibitor or H2-receptor antagonist, and two antibiotics (commonly metronidazole and tetracycline or clarithromycin). Bismuth acts as a bactericidal agent and mucosal protectant, while the combination of antimicrobials targets H. pylori through different pathways, reducing resistance development. The optimization refers to refined dosing, timing, and component selection to improve eradication rates and tolerability.
Approved indications
- Helicobacter pylori infection eradication
Common side effects
- Nausea
- Diarrhea
- Abdominal discomfort
- Metallic taste
- Black stool (bismuth-related)
- Headache
Key clinical trials
- Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans (PHASE3)
- Clinical Evaluation of a 14day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in a High Clarithromycin and Metronidazole Resistance Area Regarding Patients With Peptic Ulcer and Non Ulcer Dyspepsia (PHASE4)
- Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Optimized bismuth quadruple therapy CI brief — competitive landscape report
- Optimized bismuth quadruple therapy updates RSS · CI watch RSS
- Pontificia Universidad Catolica de Chile portfolio CI
Frequently asked questions about Optimized bismuth quadruple therapy
What is Optimized bismuth quadruple therapy?
How does Optimized bismuth quadruple therapy work?
What is Optimized bismuth quadruple therapy used for?
Who makes Optimized bismuth quadruple therapy?
Is Optimized bismuth quadruple therapy also known as anything else?
What drug class is Optimized bismuth quadruple therapy in?
What development phase is Optimized bismuth quadruple therapy in?
What are the side effects of Optimized bismuth quadruple therapy?
Related
- Drug class: All Antibiotic combination therapy / Bismuth-based H. pylori eradication regimen drugs
- Manufacturer: Pontificia Universidad Catolica de Chile — full pipeline
- Therapeutic area: All drugs in Gastroenterology / Infectious Disease
- Indication: Drugs for Helicobacter pylori infection eradication
- Also known as: Rama Intervención
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing